Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
US: FDA approval not reviewed here
The registry reports active not recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Ongoing, no longer enrolling
Registry enrollment: 1,121 participants
Study ages: 18 Years to 55 Years
No results-posting date in this record
Read trial record and resultsChecked Nov 16, 2026